vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Microvast Holdings, Inc. (MVST). Click either name above to swap in a different company.

Microvast Holdings, Inc. is the larger business by last-quarter revenue ($96.4M vs $75.1M, roughly 1.3× MEDIFAST INC). On growth, Microvast Holdings, Inc. posted the faster year-over-year revenue change (-15.0% vs -36.9%). Microvast Holdings, Inc. produced more free cash flow last quarter ($15.8M vs $-6.6M). Over the past eight quarters, Microvast Holdings, Inc.'s revenue compounded faster (8.9% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Microvast Holdings, Inc. is a battery technology company headquartered in Stafford, Texas, and publicly traded on the NASDAQ Stock Exchange. It designs, develops and manufactures battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems (ESS). Microvast has manufacturing facilities in the United States, China, and Germany.

MED vs MVST — Head-to-Head

Bigger by revenue
MVST
MVST
1.3× larger
MVST
$96.4M
$75.1M
MED
Growing faster (revenue YoY)
MVST
MVST
+21.9% gap
MVST
-15.0%
-36.9%
MED
More free cash flow
MVST
MVST
$22.4M more FCF
MVST
$15.8M
$-6.6M
MED
Faster 2-yr revenue CAGR
MVST
MVST
Annualised
MVST
8.9%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
MVST
MVST
Revenue
$75.1M
$96.4M
Net Profit
$16.5M
Gross Margin
69.4%
1.0%
Operating Margin
-10.4%
-42.7%
Net Margin
17.2%
Revenue YoY
-36.9%
-15.0%
Net Profit YoY
120.1%
EPS (diluted)
$-1.64
$0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
MVST
MVST
Q4 25
$75.1M
$96.4M
Q3 25
$89.4M
$123.3M
Q2 25
$105.6M
$91.3M
Q1 25
$115.7M
$116.5M
Q4 24
$119.0M
$113.4M
Q3 24
$140.2M
$101.4M
Q2 24
$168.6M
$83.7M
Q1 24
$174.7M
$81.4M
Net Profit
MED
MED
MVST
MVST
Q4 25
$16.5M
Q3 25
$-2.3M
$-1.5M
Q2 25
$2.5M
$-106.1M
Q1 25
$-772.0K
$61.8M
Q4 24
$-82.3M
Q3 24
$1.1M
$13.2M
Q2 24
$-8.2M
$-101.6M
Q1 24
$8.3M
$-24.8M
Gross Margin
MED
MED
MVST
MVST
Q4 25
69.4%
1.0%
Q3 25
69.5%
37.6%
Q2 25
72.6%
34.7%
Q1 25
72.8%
36.9%
Q4 24
74.1%
36.6%
Q3 24
75.4%
33.2%
Q2 24
73.2%
32.5%
Q1 24
72.8%
21.2%
Operating Margin
MED
MED
MVST
MVST
Q4 25
-10.4%
-42.7%
Q3 25
-4.6%
10.5%
Q2 25
-1.0%
17.8%
Q1 25
-1.1%
16.3%
Q4 24
0.6%
-1.2%
Q3 24
1.5%
7.1%
Q2 24
-4.7%
-118.0%
Q1 24
4.5%
-28.4%
Net Margin
MED
MED
MVST
MVST
Q4 25
17.2%
Q3 25
-2.5%
-1.2%
Q2 25
2.3%
-116.1%
Q1 25
-0.7%
53.0%
Q4 24
-72.6%
Q3 24
0.8%
13.1%
Q2 24
-4.8%
-121.4%
Q1 24
4.8%
-30.5%
EPS (diluted)
MED
MED
MVST
MVST
Q4 25
$-1.64
$0.19
Q3 25
$-0.21
$0.00
Q2 25
$0.22
$-0.33
Q1 25
$-0.07
$0.05
Q4 24
$0.08
$-0.24
Q3 24
$0.10
$0.03
Q2 24
$-0.75
$-0.32
Q1 24
$0.76
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
MVST
MVST
Cash + ST InvestmentsLiquidity on hand
$167.3M
$105.0M
Total DebtLower is stronger
$13.2M
Stockholders' EquityBook value
$198.9M
$410.5M
Total Assets
$248.0M
$1.0B
Debt / EquityLower = less leverage
0.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
MVST
MVST
Q4 25
$167.3M
$105.0M
Q3 25
$173.5M
$90.7M
Q2 25
$162.7M
$99.7M
Q1 25
$164.6M
$90.9M
Q4 24
$162.3M
$73.0M
Q3 24
$170.0M
$63.6M
Q2 24
$163.5M
$68.2M
Q1 24
$156.4M
$39.5M
Total Debt
MED
MED
MVST
MVST
Q4 25
$13.2M
Q3 25
$34.4M
Q2 25
$34.2M
Q1 25
$41.3M
Q4 24
$41.1M
Q3 24
$53.4M
Q2 24
$34.2M
Q1 24
$43.0M
Stockholders' Equity
MED
MED
MVST
MVST
Q4 25
$198.9M
$410.5M
Q3 25
$214.7M
$358.1M
Q2 25
$216.0M
$356.1M
Q1 25
$211.0M
$454.2M
Q4 24
$210.1M
$387.9M
Q3 24
$207.3M
$486.1M
Q2 24
$205.3M
$455.0M
Q1 24
$211.0M
$546.1M
Total Assets
MED
MED
MVST
MVST
Q4 25
$248.0M
$1.0B
Q3 25
$268.2M
$1.0B
Q2 25
$269.3M
$1.0B
Q1 25
$280.0M
$982.9M
Q4 24
$284.2M
$951.9M
Q3 24
$291.2M
$997.9M
Q2 24
$293.5M
$961.4M
Q1 24
$302.8M
$1.0B
Debt / Equity
MED
MED
MVST
MVST
Q4 25
0.03×
Q3 25
0.10×
Q2 25
0.10×
Q1 25
0.09×
Q4 24
0.11×
Q3 24
0.11×
Q2 24
0.08×
Q1 24
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
MVST
MVST
Operating Cash FlowLast quarter
$-5.3M
$16.4M
Free Cash FlowOCF − Capex
$-6.6M
$15.8M
FCF MarginFCF / Revenue
-8.8%
16.4%
Capex IntensityCapex / Revenue
1.8%
0.7%
Cash ConversionOCF / Net Profit
0.99×
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$56.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
MVST
MVST
Q4 25
$-5.3M
$16.4M
Q3 25
$12.1M
$15.2M
Q2 25
$-3.4M
$37.2M
Q1 25
$3.4M
$7.2M
Q4 24
$-4.9M
$6.1M
Q3 24
$9.1M
$-5.4M
Q2 24
$13.1M
$111.0K
Q1 24
$7.3M
$2.0M
Free Cash Flow
MED
MED
MVST
MVST
Q4 25
$-6.6M
$15.8M
Q3 25
$10.8M
$1.2M
Q2 25
$-4.8M
$34.3M
Q1 25
$1.9M
$4.8M
Q4 24
$-7.2M
$5.7M
Q3 24
$7.7M
$-19.6M
Q2 24
$11.1M
$-2.8M
Q1 24
$5.4M
$-8.2M
FCF Margin
MED
MED
MVST
MVST
Q4 25
-8.8%
16.4%
Q3 25
12.0%
1.0%
Q2 25
-4.5%
37.5%
Q1 25
1.6%
4.1%
Q4 24
-6.1%
5.1%
Q3 24
5.5%
-19.3%
Q2 24
6.6%
-3.4%
Q1 24
3.1%
-10.1%
Capex Intensity
MED
MED
MVST
MVST
Q4 25
1.8%
0.7%
Q3 25
1.5%
11.3%
Q2 25
1.3%
3.1%
Q1 25
1.3%
2.0%
Q4 24
1.9%
0.3%
Q3 24
1.0%
14.0%
Q2 24
1.1%
3.5%
Q1 24
1.1%
12.6%
Cash Conversion
MED
MED
MVST
MVST
Q4 25
0.99×
Q3 25
Q2 25
-1.36×
Q1 25
0.12×
Q4 24
Q3 24
8.04×
-0.41×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

MVST
MVST

Europe$35.1M36%
CN$32.5M34%
US$21.5M22%
Other$7.2M8%

Related Comparisons